Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients

Fan, Wen-Chien; Huang, Chia Chang; Yang, Ying‐Ying; Lin, Alan; Lee, Kuei–Chuan; Hsieh, Yu Chi; Fung, Chang-Phoné; Hsu, Hui‐Chi; Hou, Ming‐Chih; H, Lin

doi:10.1016/j.jmii.2015.12.006

Cited by 14 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Narciso-Schiavon et al [50] analyzed the circulating PTX3 levels in cirrhotic patients and found that higher PTX-3 levels indicated a significantly lower 90-day survival rate (54% vs. 77%). Fan et al [51] also found that acute decompensated patients with high PTX-3 levels had a higher probability of in-hospital mortality (HR: 3.94) and 3-month mortality (HR: 3.52).…”

Section: Prognostic Biomarkers Of Survival Ratementioning

confidence: 94%

Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

Chen

Wan

Wang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Liver cirrhosis is the terminal stage of most chronic liver conditions, with a high risk of mortality. Careful evaluation of the prognosis of cirrhotic patients and providing precise management are crucial to reduce the risk of mortality. Although the liver biopsy and hepatic venous pressure gradient (HVPG) can efficiently evaluate the prognosis of cirrhotic patients, their application is limited due to the invasion procedures. Child-Pugh score and the model for end-stage liver disease (MELD) score had been widely used in the assessment of cirrhotic prognosis, but the defects of subjective variable application in Child-Pugh score and unsuitability to all phases of liver cirrhosis in MELD score limit their prognostic values. In recent years, continuous efforts have been made to investigate the prognostic value of body fluid biomarkers for cirrhotic patients, and promising results have been reported. Since the collection of fluid specimens is easy, noninvasive, and repeatable, fluid biomarkers can be ideal indicators to predict the prognosis of cirrhosis. Here, we reviewed noninvasive fluid biomarkers in different prognostic functions, including the prediction of survival and complication development.

show abstract

Section: Prognostic Biomarkers Of Survival Ratementioning

confidence: 94%

Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

Chen

Wan

Wang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The prevailing opinion nowadays is that systemic PTX3 is induced in patients with chronic liver diseases [11,19] and has a positive predictive value for adverse clinical outcomes [20,21]. Liver cirrhosis is a risk factor for HCC, and PTX3 may also have a role herein [17,22].…”

Section: Introductionmentioning

confidence: 99%

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

et al. 2020

View full text Add to dashboard Cite

The acute-phase protein pentraxin-3 (PTX3) is a component of the innate immune system. Inflammation and tissue injury increased PTX3 in the injured liver, and accordingly, circulating PTX3 was induced in patients with chronic liver diseases. In the present study, PTX3 protein was determined in systemic, hepatic, and portal vein plasma of patients with liver cirrhosis to assess a possible association between hepatic PTX3 release and extent of liver injury. However, PTX3 levels were not related to disease severity. Of note, portal PTX3 levels were higher than concentrations in the hepatic vein. PTX3 in the hepatic and portal veins was negatively correlated with factor V, antithrombin 3, and prothrombin time. PTX3 did neither correlate with C-reactive protein nor galectin-3 or resistin, whereby the latter two proteins are associated with hepatic injury. PTX3 levels were not changed in cirrhosis patients with ascites or varices and did not correlate with the hepatic venous pressure gradient. Likewise, serum PTX3 was not correlated with histological steatosis, inflammation, or fibrosis stage in patients with hepatocellular carcinoma (HCC). Moreover, PTX3 was not associated with tumor node metastasis classification in HCC. Above all, PTX3 increased in hepatic, portal, and systemic blood immediately after transjugular intrahepatic portosystemic shunt (TIPS). Higher PTX3 in portal than hepatic vein plasma and further increase after TIPS suggests that the liver eliminates PTX3 from the circulation. In summary, PTX3 is not of diagnostic value in cirrhosis and HCC patients.

show abstract

“…To our knowledge, there is only a single study in the literature evaluating serum sTWEAK levels in patients with cirrhosis. In that study, Fan et al 16 have reported that serum sTWEAK levels were significantly higher in acute decompensated cirrhotic patients than controls and serum sTWEAK concentrations were found to be positively correlated with new infections, long hospital stays, high International Journal of Hematology and Oncology medical costs, and high mortality. Our results are not consistent with the findings of that study.…”

Section: Discussionmentioning

confidence: 92%

Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival.

Asıl¹

2017

UHOD

View full text Add to dashboard Cite

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily and has been implicated in the pathogenesis of several cancers. This study was conducted to investigate serum sTWEAK levels and its relation with prognosis in patients with hepatocellular carcinoma (HCC). Twenty-eight cirrhotic patients with HCC, 28 patients with cirrhosis and 30 healthy subjects were included in the study. Serum sTWEAK concentrations were measured by using commercially available enzyme-linked immune sorbent assay kits. Mean serum sTWEAK concentrations in HCC, cirrhosis and healthy control groups were 174.0±69.9 pg/ml, 221.4±61.2 pg/ml and 288.0±68.4 pg/ml respectively and the difference between the groups was statistically significant (p< 0.001). Mean sTWEAK concentration in the HCC group was significantly lower than both cirrhosis group (p= 0.009) and healty controls (p< 0.001). In the ROC curve analysis, AUC for serum TWEAK concentration to predict one-year mortality in HCC patients was 0.836 (95% CI: 0.684-0.987) and for the specified cut-off value of 148.1 pg/ml, sensitivity and specificity were 66.7% and 92.3% respectively. Kaplan-Meier survival estimates showed that, survival rate was significantly lower in patients with serum sTWEAK< 148.1 pg/ml (log-rank test, chi-square= 11.75, p= 0.001). Serum sTWEAK concentration was identified as an independent predictor of mortality in Cox regression analysis (Hazard ratio= 4.325, %95 CI: 1.080-17.326, p= 0.025). Serum sTWEAK concentration is decreased in HCC patients. Lower serum sTWEAK concentrations at the time of diagnosis are associated with poor prognosis and higher one-year mortality rates in HCC patients.Keywords: Tumor necrosis factor-like weak inducer of apoptosis, Hepatocellular cancer, Survival rate, Mortality ÖZET Serum Solubl TWEAK Konsantrasyonu Hepatoselüler Kanser Hastalarında Azalmıştır ve Düşük Kan sTWEAK Düzeyleri Kötü Sağkalımla İlişkilidirTumor necrosis factor-like weak inducer of apoptosis (TWEAK) tümör nekrozis factor ailesinin bir üyesidir ve birçok kanserin patogenezinde rol oynadığı öne sürülmüştür. Bu çalışmada hepatoselüler kanser (HCC) hastalarında serum sTWEAK düzeylerinin araştırılması amaçlanmıştır. Yirmi sekiz HCC hastası, 28 siroz hastası ve 30 sağlıklı kontrol çalışmaya dahil edilerek serum sTWEAK konsantrasyonları ELISA yöntemiyle hazır kitler kullanılarak çalışılmıştır. HCC, siroz ve sağlıklı kontrol gruplarında ortalama serum sTWEAK konsantrasyonları 174.0±69.9 pg/ml, 221.4±61.2 pg/ml ve 288.0±68.4 pg/ml olup gruplar arasındaki fark istatistiksel olarak anlamlıydı (p< 0.001). HCC grubundaki ortalama sTWEAK konsantrasyonunun gerek siroz (p= 0.009) gerek de sağlıklı kontrol (p< 0.001) gruplarından daha düşük olduğu görüldü. ROC analizinde, sTWEAK için 1 yıllık mortaliteyi öngörme açısından eğri altında kalan alan 0.836 (%95CI: 0,684-0,987) ve belirlenen148,1 pg/ml eşik değeri için duyarlılık ve özgüllük %66.7 ve %92.3 olarak bulundu.Kaplan-Meier sağkalım analizi ile serum sTWEAK konsantrasyon...

show abstract

Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients

Cited by 14 publications

References 36 publications

Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival.

Contact Info

Product

Resources

About